TVGN
Signal
Bearish Setup2
Price
1
Move-15.61%Selling pressure
Volume
1
Volume0.6× avgNormal activity
Technical
1
RSIRSI 49Momentum negative
PRICE
Prev Close
9.42
Open
9.20
Day Range7.95 – 9.41
7.95
9.41
52W Range4.14 – 75.50
4.14
75.50
5% of range
VOLUME & SIZE
Avg Volume
32.6K
FUNDAMENTALS
P/E Ratio
-1.0x
Not profitable
EPS (TTM)
Div Yield
No dividend
Performance
1D
-15.61%
5D
+6.00%
1M
+23.45%
3M
-43.21%
6M
-61.89%
YTD
-51.99%
1Y
-86.17%
Best: 1M (+23.45%)Worst: 1Y (-86.17%)
Quick Read
TrendInsufficient MA data
Momentum
BEARISH
thin 0% gross margin
Valuation
FAIR
P/E not available
Health
WEAK
CR 0.3 (low) · FCF negative
Bearish
Key MetricsTTM
Market Cap$33.29M
Revenue TTM$0.00
Net Income TTM-$21.35M
Free Cash Flow-$11.82M
Gross Margin0.0%
Net Margin0.0%
Operating Margin0.0%
Return on Equity241.4%
Return on Assets-433.9%
Debt / Equity-0.31
Current Ratio0.29
EPS TTM$-6.13
Alpha SignalsFull Analysis →
What Moves This Stock

Clinical trial data releases and regulatory milestone announcements (IND filings, Phase advancement, safety/efficacy readouts)

Capital raises and financing announcements (dilutive equity offerings, debt facilities, strategic partnerships)

Competitive developments in allogeneic T-cell therapy space (rival trial results, FDA approvals for competing platforms)

Management changes, patent developments, or manufacturing partnership announcements

Macro Sensitivity
Economic Cycle

moderate - Pre-revenue biotechs are partially insulated from GDP cycles as drug demand is non-discretionary, but financing availability is highly cyclical. During recessions, venture capital and public market appetite for speculative biotech diminishes, making capital raises more difficult or dilutive. Clinical trial timelines are generally GDP-insensitive, but partnership activity slows when large pharma companies reduce M&A budgets.

Interest Rates

High sensitivity to interest rates through multiple channels: (1) Valuation - pre-revenue biotechs are valued on discounted future cash flows 5-10+ years out, making them extremely sensitive to discount rate changes. Rising rates compress NPV of distant approvals. (2) Financing costs - higher rates increase cost of debt financing and make equity raises more dilutive as investors demand higher returns. (3) Competitive cost of capital - rising rates make safer fixed-income alternatives more attractive versus speculative biotech equity. The 10-year Treasury yield directly impacts institutional allocation to high-risk growth stocks.

Key Risks

Clinical trial failure risk - Phase I/II assets have <15% probability of ultimate FDA approval; single negative readout could render equity worthless

Regulatory pathway uncertainty for allogeneic T-cell therapies with evolving FDA guidance on manufacturing, potency assays, and safety monitoring requirements

Reimbursement uncertainty - even with approval, payer willingness to cover novel cell therapies at profitable price points remains unproven for non-CAR-T approaches

Investor Profile

momentum/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical events. Not suitable for value investors (no earnings/cash flow to value) or dividend investors (no distributions). Typical holders include biotech-focused hedge funds, retail speculators, and venture crossover funds. The 82% one-year decline and -38% three-month return indicate capitulation by institutional holders, leaving primarily distressed/event-driven players.

Watch on Earnings
Monthly cash burn rate and total cash/equivalents balance (survival metric)Clinical trial enrollment pace and data readout timelines for lead COVID-19 and EBV programsNASDAQ Biotechnology Index (NBI) performance as proxy for sector risk appetiteHigh-yield credit spreads (BAMLH0A0HYM2) indicating biotech financing environment
Health Radar
3 strong1 watch2 concern
59/100
Liquidity
0.29Concern
Leverage
-0.31Strong
Coverage
-212.1xConcern
ROE
241.4%Strong
ROIC
5744.3%Strong
Cash
$552KWatch
ANALYST COVERAGE1 analysts
HOLD
Hold
1100%
0 Buy (0%)1 Hold (100%)0 Sell (0%)
Full report →
Stock Health
Composite Score
2 of 5 signals bullish
6/10
Technicals
RSI RangeRSI 49 — Bearish momentum
Volume
Volume FlowAccumulation — institutional buying
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 0.29 — liquidity risk
Upcoming Events
EEarnings ReportMay 18, 2026
Tomorrow
DEx-Dividend DateAug 14, 2026
In 89 days
PDividend PaymentAug 31, 2026
In 106 days
Technicals
Technical SetupMIXED
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 69.2%

-4.5% vs SMA 50 · -70.6% vs SMA 200

Momentum

RSI49.5
Neutral territory
MACD+0.07
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$75.50+849.7%
EMA 200
$27.61+247.3%
EMA 50
$8.66+9.0%
Current
$7.95
52W Low
$4.13-48.0%
52-Week RangeNear 52-week low
$4.135th %ile$75.50
Squeeze SetupVolume-based
Moderate Squeeze Setup

Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.

20-Day Money Flow
Acc days:3
Dist days:1
Edge:+2 acc
Volume Context
Avg Vol (50D)37K
Recent Vol (5D)
57K+55%

Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.

Earnings & Analysts

ANALYST ESTIMATES

Consensus of 1 analyst
Analyst revisions:EPS↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$0-$7.50
Low1
FY2026(current)
$0-$10.14
Low1
FY2027
$502.3M
$502.3M$502.3M
-$13.01
Low1
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 4 consecutive quarters
Earnings HistoryTVGN
Last 6Q
-2314.5%avg beat
Beat 4 of 6 quartersMissed 2 Estimates falling
-7542%
Q2'25
-6494%
Q2'25
+40%
Q3'25
+51%
Q4'25
+20%
Q1'26
+39%
Q2'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
Flomenberg NealSee Remarks
$147
Mar 10
SELL
Flomenberg NealSee Remarks
$3K
Mar 11
SELL
Flomenberg NealSee Remarks
$3K
Mar 13
SELL
Saadi Ryan H.CEO
$1.8M
Jun 9
SELL
Flomenberg NealSee Remarks
$254K
Mar 12
SELL
Flomenberg NealSee Remarks
$81K
Mar 7
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
MORGAN STANLEY
17K
2
GEODE CAPITAL MANAGEMENT, LLC
16K
3
FMR LLC
10K
4
UBS Group AG
4K
5
VANGUARD FIDUCIARY TRUST CO
1K
6
Tower Research Capital LLC (TRC)
941
7
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.
373
8
BNP PARIBAS ARBITRAGE, SNC
282
News & Activity

TVGN News

About

No description available.

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
PeersHealth Care(7 companies)
Screen sector →
SymbolPriceDay %Mkt CapP/ERev GrwMarginELO
TVGN
$7.95-15.61%$33M1500
$66.13-5.07%$13.0B+12626.1%-14525.8%1500
$94.92-3.79%$12.6B+3288.2%-4239.0%1500
$523.69-3.00%$12.1B+43205.3%-3008.0%1500
$227.72-1.30%$11.7B+6554.5%-2868.8%1500
$57.90-0.86%$11.2B50.3+1459.3%147.7%1500
$76.67-3.79%$10.8B+2325815.3%-19.7%1500
Sector avg-4.77%50.3+398824.8%-4085.6%1500